Table 1.
Availability and cost of drug regimens for the treatment of tuberculosis in countries in the WHO European region, stratified by World Bank income classification,a in Euros
| Middle-income country | High-income country | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||
| Treatment regimenb | Availability | Cost | Availability | Cost | ||||
|
|
|
|
|
|||||
| N (%) | Median | Minimum | Maximum | N (%) | Median | Minimum | Maximum | |
|
| ||||||||
| DS-TB | 12 (100) | 44 | 15 | 152 | 31 (100) | 280 | 78 | 1084 |
| MDR/RR-TB short, BDQ 6 moc | 6 (50.0) | 764 | 542 | 15 152 | 20 (64.5) | 29 765 | 11 116 | 40 584 |
| MDR/RR-TB long, BDQ 18 moc | 7 (58.3) | 2954 | 1591 | 42 477 | 24 (77.4) | 97 808 | 34 142 | 2 16 595 |
| Pre-XDR TB, using DLM | 5 (42.7) | 7094 | 6755 | 10 916 | 15 (48.4) | 2 07 034 | 63 987 | 3 13 566 |
| Pre-XDR TB, using AM | 4 (33.3) | 2250 | 2007 | 3298 | 24 (77.4) | 1 08 459 | 37 412 | 2 49 560 |
| XDR-TB, resistant FQ, BDQ, using a carbapenemd | 4 (33.3) | 7945 | 6981 | 11 221 | 13 (41.9) | 1 41 307 | 40 237 | 2 55 550 |
| XDR-TB, resistant FQ, LZD, using a carbapenemd | 4 (33.3) | 8709 | 7965 | 11 759 | 12 (38.7) | 2 17 591 | 82 827 | 3 20 146 |
| XDR-TB, resistant FQ, BDQ, LZD, using a carbapenemd | 4 (33.3) | 8348 | 6949 | 11 528 | 10 (32.3) | 1 47 959 | 1 18 825 | 2 71 343 |
AM, amikacin; BDQ, bedaquiline; DLM, delamanid; DS, drug susceptible; FQ, fluorquinolone; LZD, linezolid; MDR, multidrug resistant; RR, rifampicin resistant; TB, tuberculosis; XDR, extensively drug resistant.
a
Drug availability data are from 43 countries; regimen cost calculation is based on data from 41 countries, not including Malta and Israel (both high-income countries).
b
Detailed regimen composition is depicted in Table S1.
c
Refers to the length of bedaquiline treatment.
d
Refers to the use of cheapest available carbapenem (meropenem or imipenem).